Clinical trial
Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
NCT00261807 · University of Maryland, Baltimore, Other · Completed
Key facts
| NCT number | NCT00261807 |
|---|---|
| Title | Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections |
| Official title | Open Label, Single Center Study to Evaluate Higher Doses of Daptomycin in the Treatment of Patients With Severe Necrotizing Skin and Soft Tissue Infections. |
| Lead sponsor | University of Maryland, Baltimore, Other |
| Collaborators | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections, Fournier's Gangrene |
| Intervention type | Drug |
| Interventions | Daptomycin 6mg/kg/day |
| Enrollment | 25 |
| Start date | Jun 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Dec 5, 2005 |
| Last update posted | Jan 27, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: